Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies

Allergology International

Volumn 66, Issue 3, 2017, Pages 398-403

  Furue, Masutaka ^a   Chiba, Takahito ^a   Tsuji, Gaku ^a   Ulzii, Dugarmaa ^a   Kido Nakahara, Makiko ^a   Nakahara, Takeshi ^a   Kadono, Takafumi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atopic dermatitis; Filaggrin; IgE autoreactivity; Th2; Th22

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOKINE; DUPILUMAB; FILAGGRIN; HISTAMINE H4 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 22; INTERLEUKIN 4; JANUS KINASE INHIBITOR; LIGAND; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; RECEPTOR ANTIBODY; ALLERGEN; AUTACOID; HLA ANTIGEN CLASS 1; T22 ANTIGEN;

ATOPIC DERMATITIS; CELL EXPANSION; CHRONICITY; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SKIN; TH2 CELL; TH22 CELL; ANIMAL; AUTOIMMUNITY; IMMUNOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION;

ALLERGENS; ANIMALS; AUTOIMMUNITY; COMBINED MODALITY THERAPY; CYTOKINES; DERMATITIS, ATOPIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN E; INFLAMMATION MEDIATORS; T-LYMPHOCYTE SUBSETS; TH2 CELLS;

EID: 85008334911     PISSN: 13238930     EISSN: 14401592     Source Type: Journal    
DOI: 10.1016/j.alit.2016.12.002     Document Type: Review

References (113)

1. Takeuchi, S., Esaki, H., Furue, M., Epidemiology of atopic dermatitis in Japan. J Dermatol 41 (2014), 200–204.
2. Sybilski, A.J., Raciborski, F., Lipiec, A., Tomaszewska, A., Lusawa, A., Samel-Kowalik, P., et al. Epidemiology of atopic dermatitis in Poland according to the Epidemiology of Allergic Disorders in Poland (ECAP) study. J Dermatol 42 (2015), 140–147.
3. Park, J., Jekarl, D.W., Kim, Y., Kim, J., Kim, M., Park, Y.M., Novel FLG null mutations in Korean patients with atopic dermatitis and comparison of the mutational spectra in Asian populations. J Dermatol 42 (2015), 867–873.
4. Nakazawa, S., Moriki, M., Ikeya, S., Sakabe, J., Tokura, Y., Atopic dermatitis presenting as generalized poikiloderma with filaggrin gene mutation. J Dermatol 41 (2014), 230–231.
5. Lee, S.C., Committee of Korean Atopic Dermatitis Association for REACH. Various diagnostic criteria for atopic dermatitis (AD): a proposal of Reliable Estimation of Atopic Dermatitis in Childhood (REACH) criteria, a novel questionnaire-based diagnostic tool for AD. J Dermatol 43 (2016), 376–384.
6. Furue, M., Kadono, T., New therapies for controlling atopic itch. J Dermatol 42 (2015), 847–850.
7. Tominaga, M., Takamori, K., Itch and nerve fibers with special reference to atopic dermatitis: therapeutic implications. J Dermatol 41 (2014), 205–212.
8. Takeuchi, S., Yasukawa, F., Furue, M., Katz, S.I., Collared mice: a model to assess the effects of scratching. J Dermatol Sci 57 (2010), 44–50.
9. Tokura, Y., Extrinsic and intrinsic types of atopic dermatitis. J Dermatol Sci 58 (2010), 1–7.
10. Martel, B.C., Litman, T., Hald, A., Norsgaard, H., Lovato, P., Dyring-Andersen, B., et al. Distinct molecular signatures of mild extrinsic and intrinsic atopic dermatitis. Exp Dermatol 25 (2016), 453–459.
11. Brenninkmeijer, E.E., Spuls, P.I., Legierse, C.M., Lindeboom, R., Smitt, J.H., Bos, J.D., Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol 58 (2008), 407–414.
12. Kabashima-Kubo, R., Nakamura, M., Sakabe, J., Sugita, K., Hino, R., Mori, T., et al. A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type. J Dermatol Sci 67 (2012), 37–43.
13. Weidinger, S., Rodríguez, E., Stahl, C., Wagenpfeil, S., Klopp, N., Illig, T., et al. Filaggrin mutations strongly predispose to early-onset and extrinsic atopic dermatitis. J Invest Dermatol 127 (2007), 724–726.
14. Mori, T., Ishida, K., Mukumoto, S., Yamada, Y., Imokawa, G., Kabashima, K., et al. Comparison of skin barrier function and sensory nerve electric current perception threshold between IgE-high extrinsic and IgE-normal intrinsic types of atopic dermatitis. Br J Dermatol 162 (2010), 83–90.
15. Esparza-Gordillo, J., Weidinger, S., Fölster-Holst, R., Bauerfeind, A., Ruschendorf, F., Patone, G., et al. A common variant on chromosome 11q13 is associated with atopic dermatitis. Nat Genet 41 (2009), 596–601.
16. Sun, L.D., Xiao, F.L., Li, Y., Zhou, W.M., Tang, H.Y., Tang, X.F., et al. Genome-wide association study identifies two new susceptibility loci for atopic dermatitis in the Chinese Han population. Nat Genet 43 (2011), 690–694.
17. Paternoster, L., Standl, M., Chen, C.M., Ramasamy, A., Bønnelykke, K., Duijts, L., et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet 44 (2011), 187–192.
18. Hirota, T., Takahashi, A., Kubo, M., Tsunoda, T., Tomita, K., Sakashita, M., et al. Genome-wide association study identifies eight new susceptibility loci for atopic dermatitis in the Japanese population. Nat Genet 44 (2012), 1222–1226.
19. Ellinghaus, D., Baurecht, H., Esparza-Gordillo, J., Rodríguez, E., Matanovic, A., Marenholz, I., et al. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. Nat Genet 45 (2013), 808–812.
20. Tamari, M., Hirota, T., Genome-wide association studies of atopic dermatitis. J Dermatol 41 (2014), 213–220.
21. Leung, D.Y., Boguniewicz, M., Howell, M.D., Nomura, I., Hamid, Q.A., New insights into atopic dermatitis. J Clin Invest 113 (2004), 651–657.
22. Gittler, J.K., Shemer, A., Suárez-Fariñas, M., Fuentes-Duculan, J., Gulewicz, K.J., Wang, C.Q., et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 130 (2012), 1344–1354.
23. Hayashida, S., Uchi, H., Takeuchi, S., Esaki, H., Moroi, Y., Furue, M., Significant correlation of serum IL-22 levels with CCL17 levels in atopic dermatitis. J Dermatol Sci 61 (2011), 78–79.
24. Czarnowicki, T., Esaki, H., Gonzalez, J., Malajian, D., Shemer, A., Noda, S., et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol 136 (2015), 941–951.
25. Tang, T.S., Bieber, T., Williams, H.C., Does “autoreactivity” play a role in atopic dermatitis?. J Allergy Clin Immunol 129 (2012), 1209–1215.
26. Cipriani, F., Ricci, G., Leoni, M.C., Capra, L., Baviera, G., Longo, G., et al. Autoimmunity in atopic dermatitis: biomarker or simply epiphenomenon?. J Dermatol 41 (2014), 569–576.
27. Sanjuan, M.A., Sagar, D., Kolbeck, R., Role of IgE in autoimmunity. J Allergy Clin Immunol 137 (2016), 1651–1661.
28. Schmid-Grendelmeier, P., Flückiger, S., Disch, R., Trautmann, A., Wüthrich, B., Blaser, K., et al. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol 115 (2005), 1068–1075.
29. Altrichter, S., Kriehuber, E., Moser, J., Valenta, R., Kopp, T., Stingl, G., Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol 128 (2008), 2232–2239.
30. Zeller, S., Rhyner, C., Meyer, N., Schmid-Grendelmeier, P., Akdis, C.A., Crameri, R., Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. J Allergy Clin Immunol 124 (2009), 278–285.
31. Kinaciyan, T., Natter, S., Kraft, D., Stingl, G., Valenta, R., IgE autoantibodies monitored in a patient with atopic dermatitis under cyclosporin A treatment reflect tissue damage. J Allergy Clin Immunol 109 (2002), 717–719.
32. Bruynzeel-Koomen, C., van Wichen, D.F., Toonstra, J., Berrens, L., Bruynzeel, P.L., The presence of IgE molecules on epidermal Langerhans cells in patients with atopic dermatitis. Arch Dermatol Res 278 (1986), 199–205.
33. Leung, D.Y., Schneeberger, E.E., Siraganian, R.P., Geha, R.S., Bhan, A.K., The presence of IgE on macrophages and dendritic cells infiltrating into the skin lesion of atopic dermatitis. Clin Immunol Immunopathol 42 (1987), 328–337.
34. Stary, G., Bangert, C., Stingl, G., Kopp, T., Dendritic cells in atopic dermatitis: expression of FcepsilonRI on two distinct inflammation-associated subsets. Int Arch Allergy Immunol 138 (2005), 278–290.
35. Tanei, R., Hasegawa, Y., Sawabe, M., Abundant immunoglobulin E-positive cells in skin lesions support an allergic etiology of atopic dermatitis in the elderly. J Eur Acad Dermatol Venereol 27 (2013), 952–960.
36. Hamid, Q., Boguniewicz, M., Leung, D.Y., Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest 94 (1994), 870–876.
37. Grewe, M., Walther, S., Gyufko, K., Czech, W., Schöpf, E., Krutmann, J., Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 105 (1995), 407–410.
38. Thepen, T., Langeveld-Wildschut, E.G., Bihari, I.C., van Wichen, D.F., van Reijsen, F.C., Mudde, G.C., et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 97 (1996), 828–837.
39. Kataoka, Y., Thymus and activation-regulated chemokine as a clinical biomarker in atopic dermatitis. J Dermatol 41 (2014), 221–229.
40. Masuoka, M., Shiraishi, H., Ohta, S., Suzuki, S., Arima, K., Aoki, S., et al. Periostin promotes chronic allergic inflammation in response to Th2 cytokines. J Clin Invest 122 (2012), 2590–2600.
41. Nakajima, R., Miyagaki, T., Oka, T., Nakao, M., Kawaguchi, M., Suga, H., et al. Elevated serum galectin-9 levels in patients with atopic dermatitis. J Dermatol 42 (2015), 723–726.
42. Koga, C., Kabashima, K., Shiraishi, N., Kobayashi, M., Tokura, Y., Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 128 (2008), 2625–2630.
43. Nograles, K.E., Zaba, L.C., Shemer, A., Fuentes-Duculan, J., Cardinale, I., Kikuchi, T., et al. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 123 (2009), 1244–1252.
44. Hayashida, S., Uchi, H., Moroi, Y., Furue, M., Decrease in circulating Th17 cells correlates with increased levels of CCL17, IgE and eosinophils in atopic dermatitis. J Dermatol Sci 61 (2011), 180–186.
45. Nograles, K.E., Zaba, L.C., Guttman-Yassky, E., Fuentes-Duculan, J., Suárez-Fariñas, M., Cardinale, I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159 (2008), 1092–1102.
46. Fujita, H., Nograles, K.E., Kikuchi, T., Gonzalez, J., Carucci, J.A., Krueger, J.G., Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci USA 106 (2009), 21795–21800.
47. Esaki, H., Czarnowicki, T., Gonzalez, J., Oliva, M., Talasila, S., Haugh, I., et al. Accelerated T-cell activation and differentiation of polar subsets characterizes early atopic dermatitis development. J Allergy Clin Immunol 138 (2016), 1473–1477.
48. Esaki, H., Ewald, D.A., Ungar, B., Rozenblit, M., Zheng, X., Xu, H., et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol 135 (2015), 153–163.
49. Sugaya, M., Morimura, S., Suga, H., Kawaguchi, M., Miyagaki, T., Ohmatsu, H., et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis. J Dermatol 42 (2015), 613–615.
50. Takeuchi, S., Esaki, H., Furusyo, N., Hayashida, S., Yamamura, K., Tsuji, G., et al. Incidence, serum IgE and TARC/CCL17 levels in atopic dermatitis associated with other allergic diseases: an update from the Ishigaki cohort. Acta Derm Venereol 95 (2015), 480–484.
51. Esaki, H., Takeuchi, S., Furusyo, N., Yamamura, K., Hayashida, S., Tsuji, G., et al. Levels of immunoglobulin E specific to the major food allergen and chemokine (C-C motif) ligand (CCL)17/thymus and activation regulated chemokine and CCL22/macrophage-derived chemokine in infantile atopic dermatitis on Ishigaki Island. J Dermatol 43 (2016), 1278–1282.
52. Kypriotou, M., Huber, M., Hohl, D., The human epidermal differentiation complex: cornified envelope precursors, S100 proteins and the ‘fused genes’ family. Exp Dermatol 21 (2012), 643–649.
53. Furue, M., Tsuji, G., Mitoma, C., Nakahara, T., Chiba, T., Morino-Koga, S., et al. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci 80 (2015), 83–88.
54. Howell, M.D., Kim, B.E., Gao, P., Grant, A.V., Boguniewicz, M., Debenedetto, A., et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 120 (2007), 150–155.
55. van den Bogaard, E.H., Bergboer, J.G., Vonk-Bergers, M., van Vlijmen-Willems, I.M., Hato, S.V., van der Valk, P.G., et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest 123 (2013), 917–927.
56. Takei, K., Mitoma, C., Hashimoto-Hachiya, A., Uchi, H., Takahara, M., Tsuji, G., et al. Antioxidant soybean tar Glyteer rescues T-helper-mediated downregulation of filaggrin expression via aryl hydrocarbon receptor. J Dermatol 42 (2015), 171–180.
57. Gutowska-Owsiak, D., Schaupp, A.L., Salimi, M., Taylor, S., Ogg, G.S., Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol 165 (2011), 492–498.
58. Seguchi, T., Cui, C.Y., Kusuda, S., Takahashi, M., Aisu, K., Tezuka, T., Decreased expression of filaggrin in atopic skin. Arch Dermatol Res 288 (1996), 442–446.
59. Gläser, R., Meyer-Hoffert, U., Harder, J., Cordes, J., Wittersheim, M., Kobliakova, J., et al. The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. J Invest Dermatol 129 (2009), 641–649.
60. Saeki, H., Nakahara, T., Tanaka, A., Kabashima, K., Sugaya, M., Murota, H., et al. Clinical practice guidelines for the management of atopic dermatitis 2016. J Dermatol 43 (2016), 1117–1145.
61. Poulsen, L.K., Hummelshoj, L., Triggers of IgE class switching and allergy development. Ann Med 39 (2007), 440–456.
62. Czarnowicki, T., Gonzalez, J., Bonifacio, K.M., Shemer, A., Xiangyu, P., Kunjravia, N., et al. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J Allergy Clin Immunol 137 (2016), 118–129.
63. Hamada, M., Furusyo, N., Urabe, K., Morita, K., Nakahara, T., Kinukawa, N., et al. Prevalence of atopic dermatitis and serum IgE values in nursery school children in Ishigaki Island, Okinawa. Jpn J Dermatol 32 (2005), 248–255.
64. Elias, P.M., Wakefield, J.S., Mechanisms of abnormal lamellar body secretion and the dysfunctional skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 134 (2014), 781–791.
65. Leung, D.Y., Harbeck, R., Bina, P., Reiser, R.F., Yang, E., Norris, D.A., et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 92 (1993), 1374–1380.
66. Powers, C.E., McShane, D.B., Gilligan, P.H., Burkhart, C.N., Morrell, D.S., Microbiome and pediatric atopic dermatitis. J Dermatol 42 (2015), 1137–1142.
67. Hampton, S., Cooke, R., The sensitivity of man to human dander, with particular reference to eczema (allergic dermatitis). J Allergy 13 (1941), 63–76.
68. Simon, F.A., The allergen of human dander present in skin of the general body surface. J Invest Dermatol 9 (1947), 329–332.
69. Simon, F.A., The allergen of human dander; its relative concentration in several skin areas and in appendages, products and derivatives of the epidermis. J Invest Dermatol 11 (1948), 203–207.
70. Adachi, K., Aoki, T., IgE antibody to sweat in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 144 (1989), 83–87.
71. Hide, M., Tanaka, T., Yamamura, Y., Koro, O., Yamamoto, S., IgE-mediated hypersensitivity against human sweat antigen in patients with atopic dermatitis. Acta Derm Venereol 82 (2002), 335–340.
72. Hiragun, T., Ishii, K., Hiragun, M., Suzuki, H., Kan, T., Mihara, S., et al. Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients. J Allergy Clin Immunol 132 (2013), 608–615.
73. Natter, S., Seiberler, S., Hufnagl, P., Binder, B.R., Hirschl, A.M., Ring, J., et al. Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB J 12 (1998), 1559–1569.
74. Flückiger, S., Mittl, P.R., Scapozza, L., Fijten, H., Folkers, G., Grütter, M.G., et al. Comparison of the crystal structures of the human manganese superoxide dismutase and the homologous Aspergillus fumigatus allergen at 2-A resolution. J Immunol 168 (2002), 1267–1272.
75. Mayer, C., Appenzeller, U., Seelbach, H., Achatz, G., Oberkofler, H., Breitenbach, M., et al. Humoral and cell-mediated autoimmune reactions to human acidic ribosomal P2 protein in individuals sensitized to Aspergillus fumigatus P2 protein. J Exp Med 189 (1999), 1507–1512.
76. Flückiger, S., Fijten, H., Whitley, P., Blaser, K., Crameri, R., Cyclophilins, a new family of cross-reactive allergens. Eur J Immunol 32 (2002), 10–17.
77. Limacher, A., Glaser, A.G., Meier, C., Schmid-Grendelmeier, P., Zeller, S., Scapozza, L., et al. Cross-reactivity and 1.4-A crystal structure of Malassezia sympodialis thioredoxin (Mala s 13), a member of a new pan-allergen family. J Immunol 178 (2007), 389–396.
78. Hradetzky, S., Roesner, L.M., Balaji, H., Heratizadeh, A., Mittermann, I., Valenta, R., et al. Cytokine effects induced by the human autoallergen α-NAC. J Invest Dermatol 134 (2014), 1570–1578.
79. Heratizadeh, A., Mittermann, I., Balaji, H., Wichmann, K., Niebuhr, M., Valenta, R., et al. The role of T-cell reactivity towards the autoantigen α-NAC in atopic dermatitis. Br J Dermatol 164 (2011), 316–324.
80. Roesner, L.M., Heratizadeh, A., Wieschowski, S., Mittermann, I., Valenta, R., Eiz-Vesper, B., et al. α-NAC-specific autoreactive CD8+ T cells in atopic dermatitis are of an effector memory type and secrete IL-4 and IFN-γ. J Immunol 196 (2016), 3245–3252.
81. Murota, H., Takeuchi, S., Sugaya, M., Tanioka, M., Onozuka, D., Hagihara, A., et al. Characterization of socioeconomic status of Japanese patients with atopic dermatitis showing poor medical adherence and reasons for drug discontinuation. J Dermatol Sci 79 (2015), 279–287.
82. Hamilton, J.D., Suárez-Fariñas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134 (2014), 1293–1300.
83. Beck, L.A., Thaçi, D., Hamilton, J.D., Graham, N.M., Bieber, T., Rocklin, R., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371 (2014), 130–139.
84. Thaçi, D., Simpson, E.L., Beck, L.A., Bieber, T., Blauvelt, A., Papp, K., et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387 (2016), 40–52.
85. Simpson, E.L., Gadkari, A., Worm, M., Soong, W., Blauvelt, A., Eckert, L., et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol 75 (2016), 506–515.
86. Cevikbas, F., Wang, X., Akiyama, T., Kempkes, C., Savinko, T., Antal, A., et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. J Allergy Clin Immunol 133 (2014), 448–460.
87. Nemoto, O., Furue, M., Nakagawa, H., Shiramoto, M., Hanada, R., Matsuki, S., et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol 174 (2016), 296–304.
88. Yamaoka, K., Okayama, Y., Kaminuma, O., Katayama, K., Mori, A., Tatsumi, H., et al. Proteomic approach to FcepsilonRI aggregation-initiated signal transduction cascade in human mast cells. Int Arch Allergy Immunol 149:Suppl. 1 (2009), 73–76.
89. Griswold, D.E., Webb, E.F., Badger, A.M., Gorycki, P.D., Levandoski, P.A., Barnette, M.A., et al. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo. J Pharmacol Exp Ther 287 (1998), 705–711.
90. Furue, M., Kitahara, Y., Akama, H., Hojo, S., Hayashi, N., Nakagawa, H., et al. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol 41 (2014), 577–585.
91. Nemoto, O., Hayashi, N., Kitahara, Y., Furue, M., Hojo, S., Nomoto, M., et al. Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: results from a randomized, vehicle-controlled exploratory trial. J Dermatol 43 (2016), 881–887.
92. Hanifin, J.M., Ellis, C.N., Frieden, I.J., Fölster-Holst, R., Stein Gold, L.F., Secci, A., et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 75 (2016), 297–305.
93. Paller, A.S., Tom, W.L., Lebwohl, M.G., Blumenthal, R.L., Boguniewicz, M., Call, R.S., et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 75 (2016), 494–503.
94. Samrao, A., Berry, T.M., Goreshi, R., Simpson, E.L., A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 148 (2012), 890–897.
95. Papp, K., Cather, J.C., Rosoph, L., Sofen, H., Langley, R.G., Matheson, R.T., et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 380 (2012), 738–746.
96. Murata, Y., Song, M., Kikuchi, H., Hisamichi, K., Xu, X.L., Greenspan, A., et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol 42 (2015), 129–139.
97. Akiyama, T., Carstens, E., Neural processing of itch. Neuroscience 250 (2013), 697–714.
98. Miyano, K., Matsushita, S., Tsuchida, T., Nakamura, K., Inhibitory effect of a histamine 4 receptor antagonist on CCL17 and CCL22 production by monocyte-derived Langerhans cells in patients with atopic dermatitis. J Dermatol 43 (2016), 1024–1029.
99. Rossbach, K., Schaper, K., Kloth, Ch, Gutzmer, R., Werfel, T., Kietzmann, M., et al. Histamine H4 receptor knockout mice display reduced inflammation in a chronic model of atopic dermatitis. Allergy 71 (2016), 189–197.
100. Di Lernia, V., Bardazzi, F., Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther 10 (2016), 533–539.
101. Levy, L.L., Urban, J., King, B.A., Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. J Am Acad Dermatol 73 (2015), 395–399.
102. Bissonnette, R., Papp, K.A., Poulin, Y., Gooderham, M., Raman, M., Mallbris, L., et al. Topical tofacitinib for atopic dermatitis: a phase 2a randomised trial. Br J Dermatol 175 (2016), 902–911.
103. Roblin, D., Yosipovitch, G., Boyce, B., Robinson, J., Sandy, J., Mainero, V., et al. Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis. Acta Derm Venereol 95 (2015), 542–548.
104. Hou, M., Sun, R., Hupe, M., Kim, P.L., Park, K., Crumrine, D., et al. Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms. Exp Dermatol 22 (2013), 210–215.
105. Murray, I.A., Nichols, R.G., Zhang, L., Patterson, A.D., Perdew, G.H., Expression of the aryl hydrocarbon receptor contributes to the establishment of intestinal microbial community structure in mice. Sci Rep, 6, 2016, 33969.
106. Aoki, T., Fukuzumi, T., Atopy-related skin rash in a normal population of infants: distribution and rates for 50 separate skin regions: cohort study from 4 months to 3.5 years. J Dermatol 42 (2015), 453–460.
107. Furue, M., Kadono, T., Psoriasis: behind the scenes. J Dermatol 43 (2016), 4–8.
108. Jariwala, S.P., Abrams, E., Benson, A., Fodeman, J., Zheng, T., The role of thymic stromal lymphopoietin in the immunopathogenesis of atopic dermatitis. Clin Exp Allergy 41 (2011), 1515–1520.
109. Togbe, D., Fauconnier, L., Madouri, F., Marchiol, T., Chenuet, P., Rouxel, N., et al. Thymic stromal lymphopoietin enhances Th2/Th22 and reduces IL-17A in protease-allergen-induced airways inflammation. ISRN Allergy, 2013, 2013, 971036.
110. Wilson, S.R., Thé, L., Batia, L.M., Beattie, K., Katibah, G.E., McClain, S.P., et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell 155 (2013), 285–295.
111. Rosado, J.A., Diez, R., Smani, T., Jardín, I., STIM and Orai1 variants in store-operated calcium entry. Front Pharmacol, 6, 2016, 325.
112. Vandenberghe, M., Raphaël, M., Lehen'kyi, V., Gordienko, D., Hastie, R., Oddos, T., et al. ORAI1 calcium channel orchestrates skin homeostasis. Proc Natl Acad Sci USA 110 (2013), E4839–E4848.
113. Chang, W.C., Lee, C.H., Hirota, T., Wang, L.F., Doi, S., Miyatake, A., et al. ORAI1 genetic polymorphisms associated with the susceptibility of atopic dermatitis in Japanese and Taiwanese populations. PLoS One, 7, 2012, e29387.